DaVita, Inc. Hits New 52-Week High at USD 213.12

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 213.12 on June 17, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 48.74%, significantly outpacing the S&P 500's growth of 24.03% during the same period. With a market capitalization of USD 11,513 million, DaVita operates in a competitive industry, showcasing a price-to-earnings (P/E) ratio of 11.00. However, the company currently does not offer a dividend yield, and its financial metrics reveal a debt-to-equity ratio of -15.25 and a return on equity of -163.56%. The stock's 52-week low stands at USD 101, highlighting the substantial upward movement it has experienced. This new high reflects the company's evolving market position and performance indicators, marking a notable point in its financial journey.